AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...
A Ministry of Health, Labor and Welfare research team has announced the five-year survival rates for people diagnosed with ...
Doctors are increasingly detecting stomach tumors at an early stage, raising hopes for lifesaving treatment for one of the deadliest types of cancer. Stomach cancer, the disease that killed country ...
MedPage Today on MSN
FDA OKs Perioperative Immunotherapy for Stomach Cancer
The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...
MedPage Today on MSN
Telehealth-Based Cancer Trial; AI-Based Cancer Biomarkers; Myeloma Survival Landmark
A community-based (real-world) study showed that artificial intelligence (AI)-informed analysis of screening mammograms ...
With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will file an approval application for Ziihera in the first half of 2026 for the treatment of ...
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and ...
PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study Using SEER 22 data, we analyzed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback